Illumina Shares Rise as New BioInsight Software Launch Appears to Lift Sentiment

Illumina (ILMN) is up 6.3% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely driver is Illumina’s October 21, 2026 product announcement expanding its BioInsight Platform with new early-access software tools aimed at AI-driven genomic analysis, workflow automation, and large-scale cohort discovery. The move may also reflect continued investor confidence in the company’s broader turnaround after stronger midyear results and raised 2026 guidance, although today’s immediate catalyst appears to be the fresh platform news.

Details:

Illumina announced DRAGEN Ultra, Workflow Orchestrator, and Learning Cohorts as new BioInsight Platform capabilities available in early access.

The company said the tools are designed to automate end-to-end informatics workflows at scale and help customers build private data lakes for scientific and clinical research.

Management introduced the new offerings at the American Society of Human Genetics meeting in Montreal, giving investors a near-term product catalyst tied to a major industry event.

Illumina has another potential investor focus point on October 29, 2026, when it is scheduled to report third-quarter results, which may be adding to positioning in the shares.

Sources:

Illumina, SEC, Illumina Investor Relations

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$ILMN Insider Trading Activity

$ILMN insiders have traded $ILMN stock on the open market 108 times in the past 6 months. Of those trades, 0 have been purchases and 108 have been sales.

Here’s a breakdown of recent trading of $ILMN stock by insiders over the last 6 months:

KEITH A. MEISTER has made 0 purchases and 93 sales selling 3,059,258 shares for an estimated $591,131,765.
SCOTT M DAVIES (Chief Legal Officer) has made 0 purchases and 3 sales selling 1,845 shares for an estimated $332,100.
SCOTT D ERICKSEN (VP, Chief Accounting Officer) has made 0 purchases and 2 sales selling 2,000 shares for an estimated $305,150.
CHRISTENSEN JAKOB WEDEL (SVP, Strategy/Corp Development) has made 0 purchases and 2 sales selling 1,733 shares for an estimated $295,168.
PATRICIA LECKMAN (SVP, Chief People Officer) has made 0 purchases and 8 sales selling 1,567 shares for an estimated $254,372.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

EARLY ACCESS

Receive ILMN Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$ILMN Hedge Fund Activity

We have seen 478 institutional investors add shares of $ILMN stock to their portfolio, and 404 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

FMR LLC added 2,976,556 shares (+192.4%) to their portfolio in Q2 2026, for an estimated $523,367,841
SESSA CAPITAL IM, L.P. removed 2,157,475 shares (-65.9%) from their portfolio in Q2 2026, for an estimated $379,348,829
SOUTHPOINT CAPITAL ADVISORS LP removed 1,700,000 shares (-81.0%) from their portfolio in Q2 2026, for an estimated $298,911,000
PRIMECAP MANAGEMENT CO/CA/ added 1,447,350 shares (+70.0%) to their portfolio in Q2 2026, for an estimated $254,487,550
AGF MANAGEMENT LTD added 1,364,815 shares (+inf%) to their portfolio in Q2 2026, for an estimated $239,975,421
NINETY ONE UK LTD added 1,356,397 shares (+37920.0%) to their portfolio in Q3 2026, for an estimated $371,218,730
WELLINGTON MANAGEMENT GROUP LLP added 1,188,004 shares (+190.1%) to their portfolio in Q2 2026, for an estimated $208,886,743

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$ILMN Government Contracts

We have seen $25,436,880 of award payments to $ILMN over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

PURCHASE OF 7 MISEQ I100S TO PERFORM WHOLE GENOME SEQUENCING (WGS) ON ALL FOODBORNE PATHOGENS ISOLATED AND ...: $805,796
ILLUMINA DRAGEN GENOMIC ANALYSIS SYSTEM: $770,996
ILLUMINA REAGENTS AND CONSUMABLES, EO 14398: $650,392
MAINTENANCE AND SERVICE CONTRACT FOR VARIOUS GOVERNMENT-OWNED ILLUMINA SEQUENCING PLATFORMS AND ANCILLARY E...: $544,728

To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard. You can access data on government contracts through the Quiver Quantitative API government contracts endpoint.

$ILMN Price Targets

Multiple analysts have issued price targets for $ILMN recently. We have seen 9 analysts offer price targets for $ILMN in the last 6 months, with a median target of $185.0.

Here are some recent targets:

Vijay Kumar from Evercore ISI Group set a target price of $200.0 on 07/06/2026
David Westenberg from Piper Sandler set a target price of $200.0 on 07/01/2026
Subbu Nambi from Guggenheim set a target price of $200.0 on 06/29/2026
Eve Burstein from Bernstein set a target price of $185.0 on 06/26/2026
Luke Sergott from Barclays set a target price of $145.0 on 06/24/2026
Casey Woodring from JP Morgan set a target price of $185.0 on 06/10/2026
Dan Leonard from RBC Capital set a target price of $170.0 on 05/15/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.